A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

← catalyst calendar

NCT07005102 · readout ≤ 1,960 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

854estimated

Sites

Countries

Australia, Belgium, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-08-03

actual

When the study began enrolling

Primary completion

Dec 2031

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2036

estimated

The whole study's end, after follow-up

First posted

2025-06-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non-Squamous Non-Small Cell Lung Cancer

Interventions

Drug: Standard of Care
Drug: Telisotuzumab Adizutecan
Drug: Osimertinib (Osi)
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

Primary outcomes

what the primary-completion date above is the date OF

Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

measured Up to Approximately 76 Months

Stage 2: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1.

measured Up to Approximately 76 Months

Number of Participants with Adverse Events (AEs)

measured Up to Approximately 76 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed